Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NYXH.BR
- Price
- 4.17
- Stock movement down
- -0.13 (-3.03%)
- Company name
- Nyxoah
- Exchange
- (BR ,
- Currency
- EUR )
- Sector
- Healthcare >Medical Instruments & Supplies
- Market cap
- 179.21M
- Ent value
- 210.98M
- Price/Sales
- 31.78
- Price/Book
- 3.52
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 35.45%
- 1 year return
- -43.87%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
NYXH.BR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 31.78 |
| Price to Book | 3.52 |
| EV to Sales | 37.41 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 43.03M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -1.89 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 10.87M |
| Net receivables | 1.36M |
| Total current assets | 35.34M |
| Goodwill | 0.00 |
| Intangible assets | 50.11M |
| Property, plant and equipment | 6.36M |
| Total assets | 93.60M |
| Accounts payable | 3.27M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 20.76M |
| Total liabilities | 42.65M |
| Shareholder's equity | 50.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.26 |
| Daily high | 4.38 |
| Daily low | 4.17 |
| Daily Volume | 35K |
| All-time high | 29.90 |
| 1y analyst estimate | 10.00 |
| Beta | 0.65 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| NYXH.BR | S&P500 | |
| Current price drop from All-time high | -86.07% | -1.08% |
| Highest price drop | -87.12% | -19.00% |
| Date of highest drop | 26 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -76.72% | -2.64% |
| Avg time to new high | - | 6 days |
| Max time to new high | 297 days | 89 days |
COMPANY DETAILS
Marketcap
179.21M
Marketcap category
Small-cap
Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Employees
183
Website
Investor relations
-
SEC filings
CEO
Country
Belgium
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2...
December 2, 2025
Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.
December 1, 2025
Nyxoah’s stock narrative is shifting as the consensus analyst price target has decreased from $12.30 to $10.00, reflecting a more conservative outlook in light of ongoing U.S. expansion efforts. This ...
November 29, 2025
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyx...
November 27, 2025
Health care stocks were edging higher premarket Wednesday, with the Health Care Select Sector SPDR F
November 26, 2025
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by s...
November 26, 2025
Nyxoah SA (NYXH) reports a successful Genio system launch in the US, securing key reimbursements and capital, while navigating cost pressures and early-stage market penetration.
November 24, 2025
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law ...
November 20, 2025
INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of eq...
November 14, 2025
Nyxoah (NYXH) delivered earnings and revenue surprises of -21.31% and +18.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
November 13, 2025
Next page